3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Withdrawn
1
Terminated
1
Recruiting
1
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Pancreatic Neoplasms
42
Urinary Bladder Neoplasms
18
Carcinoma, Non-Small-Cell Lung
18
Ovarian Neoplasms
11
Triple Negative Breast Neoplasms
10
Neoplasm Metastasis
10
Nasopharyngeal Carcinoma
10
Breast Neoplasms
10
Lymphoma, Large B-Cell, Diffuse
9
Fallopian Tube Neoplasms
9
Lung Neoplasms
8
Carcinoma, Transitional Cell
8
Biliary Tract Neoplasms
7
Recurrence
6
Gallbladder Neoplasms
6
Neoplasms
5
Cholangiocarcinoma
5
Non-Muscle Invasive Bladder Neoplasms
4
Colorectal Neoplasms
4
Urothelial Cancer
3
Stomach Neoplasms
3
Melanoma
3
Lymphoma, Non-Hodgkin
3
Lymphoma
3
Carcinoma
3
Uterine Cervical Neoplasms
2
Urethral Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Pancreatic Adenocarcinoma
2
Non Small Cell Lung Carcinoma NSCLC
2
Interventions
paricalcitol
1
ivosidenib
1
Taxes
1
Neoadjuvant Therapy
1
Losartan
1
Hydroxychloroquine
1
Gemcitabine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Pancreatic Ductal Adenocarcinoma
×
Gemcitabine
×
Clear all
NCT04827953
2024-12-30
NUMANTIA
Nelum Corp
Phase 1/2
Active not recruiting
28 enrolled